← board
CSBR
distress 0/10 · well-funded / low risk$6.13+0%today-30% from 52w high
Revenue
$46M
Liquidity
$7M
Runway
—
Shares 1y
+1%
Price & events
-11.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.5%
1D
+6.1%
1W
-1.9%
1M
+2.0%
3M
-11.5%
6M
-21.9%
1Y
+21.4%
2Y
-40.6%
5Y
-43.2%
All
Overview
- Market Cap
- $85.13M
- Volume
- 2.80K
- 52 Week Range
- $5.64 – $8.81
- Total Shares
- 13.89M
- Float Shares
- 6.07M
- Short %
- 1.13%
- % Held by Insiders
- 26.67%
- % Held by Institutions
- 41.37%
- RVOL
- 0.37x
- Beta
- 0.39
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-07-27earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 13,886,826 · 0 offerings/1y · 0 PIPEs
- 2024-11-14SC 13G/Astrategic_stake
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-03-12Craig-HallumBuy
- 2024-12-12Craig-HallumBuy
- 2024-09-12Craig-HallumHold → Buy
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.